###### Key questions

What is already known about this subject?
=========================================

-   Exhaled hydrogen is useful to evaluate intestinal digestive problems; however, the significance of exhaled hydrogen in patients with congestive heart failure has not been described.

What does this study add?
=========================

-   An overnight decrease in exhaled hydrogen during sleep is associated with a decreased cardiac index in patients with congestive heart failure.

How might this impact on clinical practice?
===========================================

-   Overnight change in exhaled hydrogen concentration could serve as possible marker of heart failure severity.

Introduction {#s1}
============

Chronic heart failure (CHF) is an emerging epidemic worldwide with high mortality and rehospitalisation.[@R1] Despite the reduced mortality and symptom relief offered by current drugs, the clinical and economic burdens of CHF remain high. Improved understanding of the pathogenesis and better diagnostic and therapeutic tools would be helpful.[@R2] Oxidative stress may play a key role in the pathology of CHF.[@R3] Stress resulting from a disturbance in the balance of reactive oxygen species (ROS) and antioxidant defence induces myocyte hypertrophy, cell apoptosis and calcium overload associated with oxidation of membrane phospholipids, proteins and DNA.[@R4] Accurate measurement of oxidative stress in vivo is challenging, but analysis of exhaled breath analysis has emerged as a non-invasive tool, and it has been evaluated in patients with CHF.[@R6] Measurement of exhaled acetone, a volatile component of ketone bodies produced by decarboxylation of acetoacetate, was found to be a useful non-invasive method of evaluating congestive haemodynamics in patients with non-ischaemic CHF.[@R7]

Hydrogen (H~2~) is a strong reducing agent in the presence of catalysts such as platinum, nickel and palladium. H~2~ selectively reduces the hydroxyl radical (·OH), a highly cytotoxic ROS, in cultured cells,[@R8] resulting in the production of free hydrogen (·OH + H~2~ → H~2~O+H). Exhaled H~2~ is useful for diagnosing small intestinal bacterial overgrowth and carbohydrate malabsorption and is applied clinically to evaluate intestinal digestive problems.[@R9] H~2~ produced by enterobacterial fermentation is absorbed into the portal circulation and excreted in the breath.[@R11] H~2~ excretion is thought to be related to systemic antioxidation activity. In patients with CHF, sympathetic activity tends to be greater at night than during the daytime. We speculated that increased production of ROS at night increases systemic H~2~ consumption, including in the intestine, causing a decrease in production of H~2~ during the night in patients with CHF. The relationship of exhaled H~2~ and haemodynamic parameters has not been described. The aim of this study was to determine whether the change in exhaled H~2~ during night sleep (=ΔH~2~) could be a marker of CHF severity. Mitochondria are damaged by ROS as well as being a source of ROS.[@R12] We also investigated the association of ΔH~2~ and the presence of mitochondrial vacuoles in electron micrographs of endomyocardial cells collected from patients with dilated cardiomyopathy (DCM).

Methods {#s2}
=======

Study population {#s2-1}
----------------

We prospectively enrolled patients with CHF with elective cardiac catheterisation. Patients were diagnosed with two major criteria or one major CHF criterion in conjunction with two minor Framingham criteria[@R14] by at least two independent cardiologists at the National Cerebral and Cardiovascular Centre between December 2014 and September 2015. After excluding those with significant coronary artery disease confirmed coronary angiography, a total of 108 patients were included in the study. Patients with a history of open heart surgery, non-invasive positive pressure ventilation and/or home oxygen therapy, end-stage renal failure, other than the heart failure diet, digestive disorders, or not willing to provide informed consent were also excluded. Fifteen patients without CHF were enrolled as the control group. The control patients were admitted to the same hospital for catheter ablation for arrhythmia during the same period, 14 with paroxysmal supraventricular tachycardia and one with premature ventricular contractions. Demographic, laboratory and echocardiographic data were collected from the patients' medical records at the time of study enrolment.

Study design and assays {#s2-2}
-----------------------

All patients were put on a hospital heart failure diet of 1600 kcal energy with 245 g carbohydrates, 60 g protein and 40 g fat. End expiration breath was collected in a sampling bag (Laboratory for Expiration Biochemistry, Nourishment Metabolism, Nara, Japan) the morning after an overnight fast and before sleep more than 2 hours after eating. Within 48 hours, the collected breath was transferred to a gas-tight glass syringe, and 1 mL was injected into a gas chromatograph with a semiconductor detector (TRIlyzer mBA-3000, Taiyo, Osaka, Japan) to measure H~2~. The concentration of the sampled gas was calculated by subtracting ambient air collected in the same bag. The overnight ΔH~2~ was calculated by subtracting the exhaled H~2~ level before sleep from that in the morning. Blood and urine sampling was performed in the early morning. Circulating albumin, uric acid (UA), creatinine, sodium, total bilirubin, C-reactive protein (CRP), high-sensitivity troponin T (hsTnT) and B-type natriuretic peptide (BNP) were assayed by certified methods in the of Clinical Laboratory Department of the National Cerebral and Cardiovascular Centre. The estimated glomerular filtration rate (eGFR) was calculated using the modified isotope dilution mass spectrometry traceable Modification of Diet in Renal Disease (IDMS--MDRD) study equation: eGFR (mL/min/1.73 m^2^) = 194 × (serum creatinine)^−1.094^ × (age)^−0.287^ × (0.739 for women).[@R15]

Echocardiography {#s2-3}
----------------

Routine echocardiography, including tissue Doppler imaging, was performed to obtain left ventricular ejection fraction (LVEF), left atrial volume index (LAVI), the ratio of early mitral inflow velocity and mitral annular early diastolic velocity (*E*/*e*′) and tricuspid regurgitation pressure gradient (TRPG), following the guidelines of the American Society of Echocardiography.[@R16] Echocardiography was performed by at least two experienced technicians in a blinded manner.

Cardiac catheterisation {#s2-4}
-----------------------

Coronary angiography was performed in patients with CHF via the radial or femoral artery in a standardised method to exclude the presence of significant coronary stenosis. Right heart catheterisation was performed to obtain haemodynamic parameters including pulmonary capillary wedge pressure (PCWP), pulmonary artery pressure (PAP), right atrial pressure (RAP) and cardiac output (CO) using a 7Fr Swan-Ganz catheter (Goodman, Nagoya, Japan). CO was determined by thermodilution, and the cardiac index (CI) was obtained by dividing CO by body surface area. Mixed venous oxygen saturation was measured at the same time. All patients in the CHF group with suspected cardiomyopathy underwent endomyocardial biopsy. Three to five pieces of ventricular tissue from different locations of the right ventricle were obtained with disposable biopsy forceps (Technowood, Tokyo, Japan). Tissue samples from 18 patients with a clinical diagnosis of DCM were processed for electron microscopy to evaluate mitochondrial morphology.

Electron microscopy {#s2-5}
-------------------

Endomyocardial tissue was fixed in 2.5% glutaraldehyde in 0.1 mol/L phosphate buffer at 4°C and postfixed in 1% buffered osmium tetroxide. The specimens were embedded in epoxy resin, and thin sections (80 nm) were cut and stained with uranyl acetate and lead citrate. The ultrastructure including mitochondria was evaluated in a blinded manner. Over 10 electron micrographs were taken using a Hitachi H-7650 transmission electron microscope (Hitachi High-Technologies, Tokyo, Japan) micrograph. At least 50 mitochondria with evaluable structure of cristae identified in a single micrograph were included in the analysis. The percentage of mitochondria with vacuole was calculated in each study participant ([figure 1](#F1){ref-type="fig"}).

![Representative electron micrograph of an endomyocardial specimen biopsied from a patient with dilated cardiomyopathy. Ultrastructural analysis to determine the percentage of mitochondria with vacuoles (arrowheads) was done to evaluate the extent of mitochondrial damage.](openhrt-2018-000814f01){#F1}

Statistical analysis {#s2-6}
--------------------

Continuous variables were reported as means±SD for normally distributed variables or as medians and IQR for non-normally distributed variables. Unpaired t-tests or Wilcoxon-Mann-Whitney tests were used to compare differences of control and CHF group values. Fisher's exact test was used to compare values of categorical variables. Spearman correlation coefficients were calculated for ΔH~2~ and each continuous variable. The analysis was performed with JMP V.10 (SAS Institute, Cary, NC, USA). A p value \<0.05 was considered statistically significant. Lack of statistical significance was reported as non-significant.

Results {#s3}
=======

Baseline characteristics {#s3-1}
------------------------

The baseline demographic and clinical characteristics of the participants are shown in [table 1](#T1){ref-type="table"}. The cause of CHF was valvular heart disease in 70 patients (65%) and non-ischaemic cardiomyopathy in 38 (35%). There were no significant differences in the demographic findings in the CHF and control groups except for a higher prevalence of hyperlipidaemia in the patients with CHF. ACE inhibitors, angiotensin II receptor blockers, β-blockers, mineralocorticoid receptor antagonists and loop diuretics were more frequently used in the CHF group than in the control group. The CHF group had lower eGFR and LVEF and higher plasma BNP levels, LAVI and *E*/*e*′ than the control subjects. Right heart catheter parameters including PCWP and CI were in the normal range in CHF group, indicating that CHF was haemodynamically compensated at the time of the study.

###### 

Baseline characteristics of the patients with chronic heart failure (CHF) and the control patients

                                          CHF                    Control             P values
  --------------------------------------- ---------------------- ------------------- ----------
  Male (%)                                57 (53)                4 (27)              0.058
  Age                                     66±15                  60±13               0.187
  BMI (kg/m^2^)                           17.5±3.0               17.8±2.6            0.730
  Vital signs                                                                        
    Heart rate (bpm)                      70±11                  75±14               0.085
    Resting systolic BP (mm Hg)           112±17                 116±13              0.379
    Resting diastolic BP (mm Hg)          64±12                  69±13               0.099
  Aetiology                                                                          
    Non-ischaemic cardiomyopathy (%)      38 (35)                --                  --
    Valvular (%)                          70 (65)                --                  --
  Coronary risk factors                                                              
    Diabetes mellitus (%)                 6 (6)                  0 (0)               0.353
    Hypertension (%)                      52 (48)                6 (40)              0.557
    Hyperlipidaemia (%)                   34 (32)                1 (7)               0.046
    Ever smoked (%)                       37 (34)                5 (33)              0.944
  Baseline use of medications                                                        
    ACE inhibitor or ARB (%)              62 (57)                3 (20)              0.006
    β-blocker (%)                         46 (43)                2 (13)              0.030
    Aldosterone receptor antagonist (%)   32 (30)                0 (0)               0.014
    Loop diuretic (%)                     48 (44)                0 (0)               \<0.001
  Laboratory data                                                                    
    Alb (g/dL)                            4.2±0.4                4.4±0.2             0.043
    UA (mg/dL)                            6.0±1.7                4.4±1.3             \<0.001
    eGFR (mL/min/1.73 m^2^)               65.5 (53.5--73.5)      74.5 (64.6--98.5)   0.028
    Sodium (mEq/L)                        140.7±3.5              141.3±1.4           0.511
    T-bil (mg/dL)                         0.8±0.5                0.7±0.3             0.282
    CRP (mg/dL)                           0.20±0.45              0.03±0.02           0.157
    hsTnT (ng/mL)                         0.012 (0.006--0.020)   --                  --
    BNP (pg/mL)                           175.4 (73.8--287.3)    25.5 (11.6--37.0)   0.001
  Echocardiogram                                                                     
    LV ejection fraction (%)              49±16                  60±2                0.013
    LA volume index (mL/m^2^)             62 (41--82)            35 (27--41)         0.039
   *E*/*e′* ratio                         14.0±6.3               7.9±2.3             \<0.001
   TRPG (mm Hg)                           28.9±10.1              21.0±7.1            0.014
  Haemodynamic data                                                                  
    Mean PCWP (mm Hg)                     11.5±6.0               --                  --
    Mean PAP (mm Hg)                      19.0±6.4               --                  --
    Mean RAP (mm Hg)                      4.3±3.0                --                  --
    CI (L/min/m^2^)                       2.96±0.6               --                  --
    SvO~2~ (%)                            68.7±5.9               --                  --

Values are means±SD, median (IQR), or n (%).

Alb, albumin; ARB, angiotensin receptor blocker; BMI, body mass index; BNP, B-type natriuretic peptide; BP, blood pressure; CI, cardiac index; CRP, C-reactive protein; E/e\', ratio of early transmitral velocity to tissue Doppler mitral annular velocity during early diastole; eGFR, estimated glomerular filtration rate; hsTnT, high-sensitivity troponin T; LA, left atrial; LV, left ventricular; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; RAP, right atrial pressure; SvO~2~, mixed venous oxygen saturation; T-bil, total bilirubin; TRPG, tricuspid regurgitation pressure gradient; UA, uric acid.

Exhaled H~2~ concentration {#s3-2}
--------------------------

In CHF group, the mean exhaled H~2~ concentration was 7.75 ppm before sleep and 3.43 ppm in the morning ([table 2](#T2){ref-type="table"}). The exhaled H~2~ concentration before sleep in the two groups was not significantly different, but in the morning, it was significantly lower in the CHF group than in the control participants. The exhaled H~2~ concentration in the CHF group was significantly lower in the morning than it was before sleep, but in the control group, it was slightly higher in the morning than before sleep ([figure 2](#F2){ref-type="fig"}). The ΔH~2~ was significantly smaller in patients with CHF compared with the control participants (−4.3±10.7 vs 2.0±7.9 ppm, p=0.030; [table 2](#T2){ref-type="table"}).

###### 

Exhaled hydrogen in patients with chronic heart failure (CHF) and controls

                           CHF           Control     P values
  ------------------------ ------------- ----------- ----------
  Hydrogen (H~2~) (ppm)                              
   Before sleep (1)        7.75±11.9     6.45±6.6    0.682
   Morning (2)             3.43±4.4      8.47±12.5   0.003
   P values ((1) vs (2))   \<0.001       0.596       
  ΔH~2~ ((2) -- (1))       --4.32±10.7   2.02±7.9    0.030

Values are means±SD.

![Assay of exhaled hydrogen (H~2~) in patients with chronic heart failure (CHF) and control participants. No significant differences in exhaled H~2~ concentration were observed before sleep (orange bars). The morning H~2~ concentration was lower in patients with CHF than in control group (green bars; p=0.003). A significant overnight decrease in exhaled H~2~ concentration was observed in CHF group (p\<0.001).](openhrt-2018-000814f02){#F2}

Correlations of H~2~ concentration and clinical characteristics {#s3-3}
---------------------------------------------------------------

Comparison of ΔH~2~, the characteristics measured by echocardiography and cardiac catheterisation revealed that ΔH~2~ was positively correlated with CI (r=0.285, p=0.003) ([figure 3A](#F3){ref-type="fig"}) but not with LVEF, *E*/*e*′, TRPG, PCWP, PAP or RAP. ΔH~2~ was negatively correlated with blood UA concentration (r=−0.200, p=0.038), eGFR (r=0.220, p=0.022), hsTnT (r=−0.324, p=0.001, [figure 3B](#F3){ref-type="fig"}) and CRP (r=−0.240, p=0.012, [figure 3C](#F3){ref-type="fig"}). We stratified the patients with CHF by increase or decrease in exhaled H~2~ concentration during night sleep ([table 3](#T3){ref-type="table"}). There were no significant differences in the age, sex ratio, general clinical data, medications, echocardiography data or laboratory data of the two subgroups. However, the CI was significantly lower in the patients with a decrease in exhaled H~2~ concentration compared with the CI in the group with an increase in the exhaled H~2~ concentration (2.85±0.61 vs 3.24±0.65 L/min/m^2^, p=0.005; [figure 4](#F4){ref-type="fig"}).

###### 

Baseline characteristics of study patients and overnight change in exhaled H~2~ (ΔH~2~)

                                   Decrease H~2~          Increase H~2~          P values
  -------------------------------- ---------------------- ---------------------- ----------
  Male (%)                         45 (58)                12 (40)                0.101
  Age                              67±14                  63±16                  0.198
  General examination                                                            
    BMI (kg/m^2^)                  17.6±3.1               17.3±2.5               0.701
    Heart rate (bpm)               69±10                  71±14                  0.337
    Resting systolic BP (mm Hg)    112±17                 112±15                 0.910
    Resting diastolic BP (mm Hg)   64±13                  63±10                  0.570
  Laboratory data                                                                
    Alb (g/dL)                     4.2±0.4                4.3±0.3                0.203
    UA (mg/dL)                     6.1±1.8                5.8±1.6                0.547
    eGFR (mL/min/1.73 m^2^)        66.1 (53.1--72.6)      64.6 (56.7--77.6)      0.914
    Sodium (mEq/L)                 140.7±3.7              140.8±2.7              0.900
    T-bil (mg/dL)                  0.8±0.4                0.9±0.6                0.181
    CRP (mg/dL)                    0.24±0.52              0.09±0.11              0.120
    hsTnT (ng/mL)                  0.014 (0.008--0.022)   0.007 (0.004--0.018)   0.284
    BNP (pg/mL)                    148 (74--301)          186 (100--275)         0.601
  Echocardiogram                                                                 
    LV ejection fraction (%)       48±15                  49±18                  0.765
    LA volume index (mL/m^2^)      62 (39--88)            64 (49--83)            0.367
   *E*/*e′* ratio                  13.6±6.0               15.0±6.9               0.342
    TRPG (mm Hg)                   30.1±10.3              25.6±8.9               0.059
  Haemodynamic data                                                              
    Mean PCWP (mm Hg)              11.3±5.8               11.8±6.6               0.717
    Mean PAP (mm Hg)               19.0±6.1               18.9±7.3               0.932
    Mean RAP (mm Hg)               4.0±2.3                5.2±4.1                0.077
    CI (L/min/m^2^)                2.85±0.6               3.24±0.7               0.005
    SvO~2~ (%)                     68.7±6.2               68.6±4.8               0.962

Values are means±SD, median (IQR), or n (%).

Alb, albumin; BMI, body mass index; BNP, B-type natriuretic peptide; BP, blood pressure; CI, cardiac index; CRP, C-reactive protein; E/e\', ratio of early transmitral velocity to tissue Doppler mitral annular velocity during early diastole; eGFR, estimated glomerular filtration rate; hsTnT, high-sensitivity troponin T; LA, left atrial; LV, left ventricular; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; RAP, right atrial pressure; SvO~2~, mixed venous oxygen saturation; T-bil, total bilirubin; TRPG, tricuspid regurgitation pressure gradient; UA, uric acid.

![Correlation of change in H~2~ concentration (△H~2~) haemodynamics or laboratory parameters. (A) ΔH~2~ was positively correlated with cardiac index (CI; r=0.285, p=0.003). (B) ΔH~2~ was negatively correlated with high-sensitivity troponin T (hsTnT; r =−0.324, p=0.001). (C) ΔH~2~ was negatively correlated with C-reactive protein (CRP; r=−0.240, p=0.012).](openhrt-2018-000814f03){#F3}

![Comparison of cardiac index (CI) in patients with overnight decreased exhaled hydrogen (H~2~) concentration and increased exhaled H~2~ concentration. CI was significantly lower in the decreased exhaled H~2~ than in the other group (2.85±0.61 vs 3.24±0.65 L/min/m^2^, p=0.005). Data are means±SD.](openhrt-2018-000814f04){#F4}

Mitochondrial morphology {#s3-4}
------------------------

Evaluation of the electron micrographs of the endomyocardial biopsy tissue obtained from 18 patients revealed a significant positive correlation of ΔH~2~ and percentage of mitochondria with vacuoles (r=0.61, p=0.007; [figure 5](#F5){ref-type="fig"}), suggesting that the overnight decrease in exhaled H~2~ concentration was related to mitochondrial damage.

![The percentage of mitochondria in endomyocardial tissue cells with vacuoles and overnight change in H~2~ concentration had a significant positive correlation (r=−0.61, p=0.007).](openhrt-2018-000814f05){#F5}

Discussion {#s4}
==========

The main study findings are the significant overnight decrease in exhaled H~2~ concentration in patients with CHF compared with the control participants and the inverse correlation of the decrease with CI. Electron microscopy of myocardial tissue suggested that mitochondrial damage might have been associated with H~2~ consumption during the night-time hours. To the best of our knowledge, this is the first study to demonstrate the significance of a decrease in exhaled H~2~ concentration in patients with CHF. The cause of the change in exhaled hydrogen concentration during the night has not been determined. H~2~ included in exhaled air is thought to be produced by anaerobic fermentation in the lower gastrointestinal tract. The significance of hydrogen production by enteral anaerobic fermentation is not clear, but a previous study in a rat hepatic ischaemia--reperfusion model suggested an antioxidative effect.[@R17] Altered intestinal function and changes of the enterobacterial flora have been reported in patients with CHF.[@R18] Given the available evidence and the presence of autonomic hyperactivity at night in patients with CHF, it is possible that hydrogen derived from enteral anaerobic fermentation is consumed at night by antioxidant activity, resulting in a decrease in the exhaled hydrogen concentration in patients with CHF in the morning. At night, before sleeping, the exhaled H~2~ concentration in patients with CHF and in control participants was comparable, suggesting that some homeostatic mechanism may increase enteric H~2~ production in the daytime to maintain the body balance in CHF.

In this study, echocardiography and right heart catheterisation were used to evaluate the relationship between ΔH~2~ and heart function in the patients with CHF. ΔH~2~ was significantly correlated with CI but not with echocardiographic parameters or haemodynamic indices of volume overload such as PCWP, PAP and RAP. The association of an overnight decrease in exhaled H~2~ concentration with a lower CI can be explained in part by an increase in ROS accompanied by a decrease in tissue perfusion. A decreased CI as a consequence of a haemodynamic deterioration in patients with CHF may induce intestinal motility disturbance that results in altered enterobacterial flora and decrease in exhaled H~2~.[@R20]

In this study, electron micrographs of tissue from patients with DCM confirmed a significant correlation between ΔH~2~ and the percentage of mitochondria having vacuoles. Mitochondrial vacuoles reflect abnormal cristae patterns because of mitochondrial DNA damage by ROS and impaired mitochondrial quality.[@R13] The results indicate that increased ROS production may result in phenotypically damaged mitochondria in patients with CHF that are associated with increased overnight consumption of H~2~. Antioxidants, including H~2~, may ameliorate myocardial failure. Inhalation of H~2~ gas was found to attenuate the deleterious changes induced by intermittent hypoxia in cardiomyopathic hamsters.[@R22] Inhalation of H~2~ gas was also found to protect the heart and to reduce LV remodelling after ischaemia--reperfusion injury.[@R23] These results indirectly support our finding that H~2~ might reduce ROS in patients with CHF.

Breath analysis has the advantages of being non-invasive and easy to perform and repeat, which favour use as a disease marker. We recently reported that exhaled acetone may be useful as a biomarker of pulmonary congestion in patients with CHF comparable with blood BNP.[@R7] Overnight decrease in exhaled H~2~ may serve as surrogate of CI and ROS production in patients with CHF. Although exhaled H~2~ derives from anaerobic metabolism in the lower gastrointestinal tract that is easily affected by variety of factors such as diet, it may be a candidate marker in CHF. Additional research with long-term follow-up is warranted, as biomarkers that can estimate the severity of CHF are needed.[@R24]

Study limitations {#s4-1}
-----------------

First, this was a monocentre study that included a small number of cases. Although the pathological examination was conducted in a blinded manner, to improve objectivity, multicentre prospective trials would be helpful. Second, 65% of the patients had valvular heart disease and most were in need of valve surgery. Consequently, the study population may not be representative of all patients with CHF. Third, the use of antioxidant drugs was not considered. Angiotensin II receptor blockers, β-adrenoceptor blockers and statins, which were used by most of the patients in this study, have shown antioxidant activity,[@R25] and may have influenced ROS production. Finally, since the reaction that H~2~ selectively reduces the hydroxyl radical (·OH) has not been demonstrated in vivo, basic experiments to prove this reaction in vivo are also necessary.

Conclusions {#s5}
===========

In conclusion, this study demonstrated that an overnight decrease in exhaled H~2~ during sleep was associated with a decreased CI in patients with CHF. H~2~ may be a marker of CHF.
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